New valve could change the way patients around the world are treated for aortic valve disease.
Abbott has received U.S. Food and Drug Administration (FDA) approval for the most advanced MitraClip heart valve repair device to treat mitral regurgitation. The latest approval for the fourth-generation MitraClip device, MitraClip G4, puts new enhancements into the hands of physicians across the U.S. by delivering an expanded range of clip sizes, an alternative leaflet grasping feature […]
In patients with chest pain who are at high risk for CAD but have no known disease, evaluation with coronary CT angiography (CTA) is associated with an improvement in long-term outcomes as compared with function tests, while functional testing—namely quantitative positron emission tomography (PET)—may be better suited to identifying patients at low risk for events […]
People who skip breakfast and eat dinner near bedtime have worse outcomes after a heart attack, according to research published in the European Journal of Preventive Cardiology,1 a journal of the European Society of Cardiology (ESC). The study found that people with both eating habits had a four to five times higher likelihood of death, another heart attack or […]
Patients presenting to the emergency department (ED) with new, symptomatic A-fib do not necessarily need to undergo immediate cardioversion, as is now common practice, the RACE 7 ACWAS trial indicates
Heart failure (HF) admissions and total number of hospitalized days are reduced in the year after undergoing TAVR compared with the year prior to the procedure, contributing to a significant decrease in Medicare costs, according to findings from an observational study. Admissions for noncardiac causes such as infections and bleeding, however, crept higher after the […]
“US registry data presented this week at EuroPCR back the use of Sapien 3 (Edwards Lifesciences) for TAVR in intermediate-risk patients, matching the safety and efficacy results seen in the PARTNER II S3 (S3i) trial.”
“A significant update to the PROGRESS-CTO (PROspective Global Registry for the Study of Chronic Total Occlusion Intervention) International Registry was presented as late-breaking clinical science at 2018 Society for Cardiovascular Angiography and Interventions (SCAI) Scientific Sessions. “
“Technology leaders contacted Rumsfeld, the college’s chief innovation officer, after the ACC published a “roadmap for innovation” in 2017 (J Am Coll Cardiol 2017;70:2696-718).”
Stay Up-To-Date on jobs and industry news.
Sign up for the CathLab.com newsletter today!